Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Xetra  >  Bayer AG    BAYN   DE000BAY0017

BAYER AG

(BAYN)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Bayer : Drug Iberogast Under Investigation -Handelsblatt

share with twitter share with LinkedIn share with facebook
share via e-mail
0
07/22/2019 | 04:27am EDT

--Bayer AG's (BAYN.XE) digestive medication Iberogast is at the center of an investigation by the Cologne public prosecutor's office for a possible connection with the death of a person who took the medication, German business magazine Handelsblatt reports.

--According to the publication, the conglomerate refused to add warnings about possible liver damage and failure to the drug's package leaflet for years.

--The company only added them last year, when it became known that a woman in Germany died of liver failure and interior bleeding who previously took the medication, Handelsblatt reports.

--Bayer wasn't immediately available for comment.

Full story (in German): https://bit.ly/2Y9Sncd

Write to Barcelona editors at barcelonaeditors@dowjones.com

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on BAYER AG
08/16Materials up Amid Hopes for Stimulus -- Materials Roundup
DJ
08/13Bayer and LANXESS to sell their stakes in Currenta to Macquarie Infrastructur..
AQ
08/12CORRECTION : Weed Killer-Label story
AQ
08/12No-deal Brexit could deepen Europe's shortage of medicines - experts
RE
08/09Materials Down After Trump Comments on Trade Negotiations -- Materials Roundu..
DJ
08/09BAYER MEDIATOR : $8 Billion Roundup Settlement Report 'Pure Fiction' -- 4th Upda..
DJ
08/09EUROPE : Italy leads European shares lower on political uncertainty
RE
08/09BAYER MEDIATOR : $8 Billion Roundup Settlement Report 'Pure Fiction' -- 3rd Upda..
DJ
08/09NEWS HIGHLIGHTS : Top Company News of the Day
DJ
08/09NEWS HIGHLIGHTS : Top Company News of the Day
DJ
More news
Financials (EUR)
Sales 2019 46 199 M
EBIT 2019 8 364 M
Net income 2019 3 352 M
Debt 2019 37 554 M
Yield 2019 4,42%
P/E ratio 2019 20,2x
P/E ratio 2020 13,7x
EV / Sales2019 2,11x
EV / Sales2020 2,00x
Capitalization 60 140 M
Chart BAYER AG
Duration : Period :
Bayer AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BAYER AG
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 29
Average target price 77,86  €
Last Close Price 64,49  €
Spread / Highest target 90,7%
Spread / Average Target 20,7%
Spread / Lowest Target -39,9%
EPS Revisions
Managers
NameTitle
Werner Baumann Chairman-Management Board
Werner Wenning Chairman-Supervisory Board
Wolfgang U. Nickl Chief Financial Officer
Katharina Jansen Head-Science & Research
Hartmut Klusik Head-Human Resources, Technology & Sustainability
Sector and Competitors
1st jan.Capitalization (M$)
BAYER AG6.69%65 567
JOHNSON & JOHNSON1.15%344 517
ROCHE HOLDING LTD.12.24%235 575
ROCHE HOLDING13.20%235 575
MERCK AND COMPANY11.32%213 689
NOVARTIS17.81%202 958